Reklāma
Becton, Dickinson Boosts FY24 Ad, EPS Outlook - Update
(RTTNews) - While reporting financial results for the third quarter on Thursday, medical technology company Becton, Dickinson and Co. (BDX) raised its adjusted earnings guidance for fiscal 2024, while trimming annual revenue outlook.
For fiscal 2024, the company now projects adjusted earnings in a range of $13.05 to $13.15 per share on revenues growth of about 3.7 percent to about $20.1 billion and adjusted revenues between $20.1 billion to $20.2 billion, with organic revenue growth of 5.0 to 5.25 percent.
Previously, the company expected adjusted earnings in a range of $12.95 to $13.15 per share on revenues between approximately $20.1 billion to $20.3 billion, with organic revenue growth of 6.1 to 7.7 percent.
On average, analysts polled by Thomson Reuters expect the company to report earnings of $13.04 per share on revenue growth of 4.4 percent to $20.23 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
BD Recalls ChloraPrep Clear 1 ML Applicators
BD Announces Global Commercial Release Of New BD FACSDiscover S8 Cell Sorters
BD Gets FDA 510(k) Clearance For Fingertip Blood Collection Device
BD To Sell Surgical Instrumentation Platform To STERIS For $540 Mln
Becton, Dickinson Boosts FY23 Outlook - Update
Becton, Dickinson Boosts FY23 Outlook - Update
Becton, Dickinson Guides FY23 Below Estimates; Boosts Dividend 4.6% - Update
